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Abstract
Background: Pim-1 is a serine-threonine kinase which promotes early transformation, cell proliferation and cell
survival during tumorigenesis. Several studies have demonstrated that Pim-1 kinase play a role in different cancer
types, however, the function of Pim-1 in bladder cancer is poorly understood.
Methods: Expression and localization of Pim-1 in human normal and malignant bladder specimens were examined
by Immunohistochemistry and Pim-1 staining score was compared with several clinicopathologic parameters. To
further demonstrate the biological function of Pim-1 in bladder cancer, its expression was validated in five bladder
cancer cell lines by western blot and immunohistochemistry analyses. Subsequent knockdown of Pim-1 was
achieved by lentivirus encoding small interfering RNA, and the effect of Pim-1 on bladder cell survival and drug
sensitivity were further assessed by colony formation and cell proliferation assays.
Results: When compared with normal epithelium, Pim-1 was overexpressed in bladder cancer epithelium, and the
expression level was higher in invasive bladder cancer than Non-invasive bladder cancer specimens. Pim-1 was also
detected in all the bladder cancer cell lines examined in our study. Moreover, the knockdown of Pim-1 significantly
inhibited bladder cancer cell growth and also sensitized cells to chemotherapeutic drugs in vitro.
Conclusions: Our results in this study suggest that Pim-1 may play a role in bladder cancer initiation and
progression. Since Pim-1 is also involved in bladder cancer cell survival and drug resistance, Pim-1 is a potential
candidate for targeted therapy in bladder cancer.
Background
Bladder cancer is one of the most common types of
cancer globally, with approximately 75% of the diag-
nosed tumors classified as Non-invasive tumor (Ta, Tis,
or T1). Treatment of Non-invasive tumor includes
transurethral resection (TUR) with or without intravesi-
cal instillation therapy, but the recurrence rate is high,
ranging from 50% to 70%. In addition, an average of
10% to 20% for Non-invasive tumors may further pro-
gress to muscle-invasive disease, thus lead to eventual
radical Cystectomy and urinary diversion [1-3]. In this
context, clinicians face challenges to identify the novel
therapeutic targets for bladder cancer.
Pim-1 is overexpressed in several types of cancer,
including lymphoid and haematopoietic malignancies
[4], prostate cancer [5], squamous cell carcinomas [6],
gastric carcinoma and colorectal carcinomas [7].
Currently available studies have demonstrated that the
expression of Pim-1 can be predictive of tumor outcome
following chemotherapy and surgery, and it is correlated
with the enhanced metastatic potential of the tumor [8].
As a member of serine/threonine kinase family, Pim-1
has multiple roles in tumorigenesis such as promoting
transformation and cell proliferation partly through reg-
ulation of cell cycle and transcription by phosphorylat-
ing of number of substrates including cdc25A/C, HP1,
and p100 [9-11]. Moreover, it has been shown that Pim-
1 may play a role in the regulation of the survival signal-
ing through the modulation of Bcl-2 family member
including Bad, Bcl-2 and Bcl-XL [12-14]. However, the
expression and significance of Pim-1 in bladder cancer
remains unknown. Therefore, the aims of the present
study are to investigate the expression level of Pim-1 in
bladder cancer tissue and study its function in the
pathogenesis and progression of bladder cancer.
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Patient samples
Sixty-six clinical bladder samples isolated from the First
Affiliated Hospital of the Sun Yat-Sen University
(Guangzhou, China), were examined in the present
study. All patients including forty-eight men (72.3%)
and eighteen women (27.7%), had been treated for
urothelial carcinoma of the bladder by transurethral
resection of bladder (TUR) or Cystectomy and were
diagnosed with a bladder cancer for the first time at an
average age of 56 years (range, 33-78 years). Pathologic
staging and grading were performed according to the
2002 TNM classification sy s t e ma n dW o r l dH e a l t h
Organization criteria, respectively. The use of the
human tissue in this study was approved by the Ethics
Council of the Sun Yat-Sen University for Approval of
Research Involving Human Subjects.
Immunohistochemistry
All 5μm thick paraffin sections were deparaffinized
with xylene and rehydrated through graded alcohol
washes, followed by antigen retrieval by heating sec-
tions in sodium citrate buffer (10 mmol/L, pH6.0) for
30 minutes. Endogenous peroxidase activity was
blocked with 30 min incubation in 0.03% H2O2 in
methanol. The slides were then blocked by incubation
in normal goat serum (dilution 1:10) in PBS (pH 7.4)
and subsequently incubated for monoclonal mouse
IgG1 anti-Pim-1 antibody(sc-13513; Santa Cruz Bio-
technology, Santa Cruz, CA, USA) with 1:30 dilution
at 4°C overnight. Following this step, slides were trea-
ted with biotin-labeled anti-IgG and incubated with
preformed avidin-biotin peroxidase complex. Control
staining of the same sections was performed with the
preimmune primary antibody, and no Pim-1 immunos-
taining was observed in these sections. The sections
were briefly counter-stained with hematoxylin. IHC
reactions for all samples were repeated at least three
times, and typical results were illustrated.
Scoring and Statistical analyses
The staining of Pim-1 was graded in each sample based
on the intensity of the immunoreactivity in the cancer
cells and was stratified as strong staining (3), moderate
staining (2), weak staining (1) and negative (0). Using
these criteria, the immunostaining results were evaluated
i n d e p e n d e n t l yb yX P Ma n dB H .T h ec o r r e l a t i o no f
interobserver was calculated from the independent eva-
luations. For cases with discrepancy, a consensus was
reached during a common evaluation session. The sta-
tistical analyses were carried out by using SAS version
9.0 statistics software (SAS Institute, Inc., Cary, NC).
Cell culture and lentiviral infection
Bladder cancer cell lines T24, UM-UC-3, 5637, J82 and
RT-4 were purchased from the American Type Culture
Collection. UM-UC-3 and T24 cells were grown in Dul-
becco’s modified Eagle’s medium. 5637, J82 and RT-4
cells were maintained in RPMI 1640 with 10% fetal
bovine serum and 1% (v/v) penicillin and streptomycin
(100 μg/ml) and maintained at 37°C in a 5% CO2 atmo-
sphere. The infection of lentivirus of Pim-1 siRNA was
carried out as reported previously [15].
Western Blot
Western blot was performed as described previously
[16]. Briefly, the equal amounts of sample were resolved
on a SDS polyacrylamide gel and transferred to a polyvi-
nylidene difluoride membrane. Blots were incubated
with the indicated primary antibodies overnight at 4°C
and followed by detection with horseradish peroxidase-
conjugated secondary antibody. The monoclonal anti-
Pim-1 antibody was used at the dilution of 1:300,
whereas anti-tubulin, Bcl-2, Bad and p-Bad (Ser112)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) were
used at the dilution of 1:2,000.
Cell immunoperoxidase staining
Bladder cancer cells were plated onto the glass slides.
After 24 h, cells were fixed with ice-cold acetone. The
endogenous peroxides activity was inactivated by incu-
bating cells with 0.03% H2O2 for 10 min. Slides were
then incubated with Pim-1 antibody at room tempera-
ture for 1 hour and followed by horseradish peroxides-
conjugated anti-mouse Ig (Chemicon; 1:500 dilutions).
Finally, slides were incubated with biotin-labeled anti-
IgG avidin-biotin peroxidase complex and developed
with DAB Solution.
Colony formation assay
The cells (1 × 10
4) were seeded in 6-well plate and
infected with the lentivirus expressing control siRNA or
Pim-1 siRNA. Cell culture was maintained in complete
medium for two weeks. The cell colonies were then
visualized by Coomassie blue staining.
Drug-sensitivity assay
Cells were infected with lentivirus encoding control
siRNA or Pim-1 siRNA. At 48 h post-infection, cells
were seeded on 96-well plate at a density of 6 × 10
3
cells/well. After 24 h, cells were treated with various
doses of Doxorubicin or Docetaxel (Sigma, St Louis,
MO, USA) for another 48 h. The cells viability was mea-
sured by the WST-1 (Roche) assay following the manu-
facturer’s instructions.
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Overexpression of Pim-1 in human bladder cancer
specimens
To validate the expression of Pim-1 protein in bladder
cancer, human bladder specimens containing normal
epithelium (n = 21) and malignant tissues (n = 45)
were studied by immunohistochemistry using Pim-1
antibody. The staining data showed that Pim-1 expres-
sion is weakely detect in the epithelial cells of normal
bladder epithelium, however, most of the malignant
bladder epithelial cells exhibited Pim-1 immunoreactiv-
ity in both cytoplasm and nuclear (Figure 1). For
further analysis, the immunoreactivity of Pim-1
was divided into negative (score 0-1) vs. positive (score
2-3) subgroups. Detailed staining scores in normal and
malignant bladder specimens are presented in Table 1,
which showed that Pim-1 expression is significantly
higher in bladder cancer specimens (84.4%) than in
normal specimens (9.5%) (p < 0.001), suggesting an
overexpression of Pim-1 at the translational level in
bladder cancer.
To explore potential correlations between the
expression of Pim-1 and tumor progression, malignant
bladder specimens were further classified into Non-
invasive (Tis, Ta and T1) and invasive (≥T2) groups.
T h ed a t a( T a b l e2 )s h o w st h a tt h es t a i n i n gi n t e n s i t yo f
Pim-1 is increased in invasive bladder carcinoma
samples (95%) when compared with Non-invasive blad-
der cancer specimens (76%)(p < 0.01). However,
correlation of Pim-1 within different tumor grades was
not observed (data not shown). Taken together, Pim-1
may be associated with bladder cancer initiation and
progression.
Expression profile of Pim-1 in bladder cancer cell lines
In order to further demonstrate the role and function of
Pim-1 in bladder cancer, the expression level of Pim-1
was validated in bladder cancer cell lines using western
blot. As shown in Figure 2A, Pim-1 is expressed in all
five bladder cancer cell lines at variable levels, with the
maximum level in highly invasive cancer cell lines T24
and UM-UC-3.
The localization of Pim-1 in bladder cancer cells was
confirmed by immunoperoxidase staining and as the
results showed that Pim-1 was detected in all human
bladder cell lines examined, including T24, UM-UC-3,
5637, J82 and RT-4. Representative images are pre-
sented in Figure 2B. The positive signals were primar-
ily immunolocalized in both cell cytoplasm and
nucleus, while some cell membrane staining is also
detected.
Figure 1 Overexpression of Pim-1 in human bladder cancer specimens. Pim-1 is overexpressed in both cytoplasm and nucleus of bladder
cancer cells. Normal bladder epithelium cells show no or minimal staining (A&D). Bladder cancer cells show cytoplasm and nucleus positive
staining (B&E). Invasive bladder cancer cells show strong staining(C&F). Magnification × 200 (A, B, C), or × 400 (D, E, F).
Table 1 Pim-1 immunostaining intensity in human
normal and maligancy bladder tissues
groups n negtive positive
Normal 21 19(90.5%) 2(9.5%)
Malignancy 45 7(15.6%) 38(84.4%)
p < 0.001
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To examine the biological significance of Pim-1, targeted
knockdown of Pim-1 was achieved by lentivirus encoding
siRNA specific for Pim-1 in T24 and UM-UC-3 cells,
which express relatively high levels of Pim-1. The Pim-1
siRNA using in our experiments has been previously
shown to specific knockdown Pim-1 in multiple prostate
cancer cell lines [17,18]. As shown in Figure 3A, downre-
gulation of Pim-1 decreased Phospho-Bad and Bcl-2
levels that are known to be regulated by Pim-1. Further-
more, downregulation of Pim-1 could also inhibit the cell
growth and proliferation in vitro (Figure 3B), suggesting
that Pim-1 may be important for the growth and survival
of bladder cancer cells.
Knockdown of Pim-1 sensitizes bladder cancer cells to
chemotherapy in vitro
As Pim-1 is involved in drug resistance in some cancer
types and adjuvant intravesical chemotherapy is one of
the most common treatments in bladder cancer, we
tested whether Pim-1 is also involved in drug response
of bladder cancer cells. T24 and UM-UC-3 cells were
treated with lentivirus encoding the siRNA specific for
vector control or Pim-1 and then were tested for their
responses to chemotherapeutic drugs. As shown in
Figure 3C, downregulation of Pim-1 sensitized T24 and
UM-UC-3 cells to Doxorubicin (DOX) and Docetaxel
(DTX) when compared to the vector control. Our data
implied that Pim-1 may contribute to the resistance of
apoptosis and survival of bladder cancer cells in
response to cytotoxic drugs.
Discussion
I nt h ep r e s e n ts t u d yw ed e m o n s t r a t e df o rt h ef i r s tt i m e
that, Pim-1 was increased in human bladder cancer
epithelium as compared with that in normal bladder tis-
sue. When the tumors were stratified by Non-invasive
and invasive, a statistically significant increase of Pim-1
expression was found in the subgroup of invasive tumor
when compared with that in the Non-invasive tumor.
Pim-1 was also detected in all human bladder cancer
cell lines tested in our study. Knockdown Pim-1 led to
decreased phosphorylation of Bad and reduced expres-
sion of Bcl-2. Furthermore, downregulation of Pim-1
inhibited the bladder cancer cells growth and sensitized
them to chemotherapy in vitro. Further evaluation of
the prognostic significance of Pim-1 in a larger cohort
with sufficient follow-up times will allow better under-
stand of the clinical significance of Pim-1.
Table 2 Pim-1 immunostaining intensity in No-invasive
and Invasive bladder tumors
groups n negtive positive
Non-invasive 25 6(24.0%) 19(76.0%)
Invasive 20 1(5%) 19(95.0%)
p < 0.01
Figure 2 Expression profile of Pim-1 in bladder cancer cell lines. A. Expression profile of Pim-1 in bladder cancer cell lines. Cell lysate from
five bladder cancer cell lines were examined by western blot for Pim-1. Tubulin is as the loading control. B. The expression and localization of
Pim-1 in human bladder cancer cell lines. Cells were immunoperoxidase stained with Pim-1 antibody as described as methods. Original
magnification ×400.
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A. Knockdown of Pim-1 decreased the phosphorylation of Bad and the expression of Bcl-2. The cells were infected lentivirus siRNA specific for
Pim-1(si Pim-1) or vector control. At 48 h postinfection, cells were lysed and the lysates were subjected to western blot with indicated antibody.
B. Downregulation of Pim-1 inhibited the bladder cancer cell growth. Total of 1 × 10
4 T24 and UM-UC-3 cells were plated in each well of a 6-
well plate and infected with lentivirus encoding Pim-1 siRNA or vector control siRNA. The cell culture was maintained in complete medium for
two weeks. Finally, the cell colonies were visualized by Coomassie blue staining. C. Decreased expression of Pim-1 sensitized bladder cancer cells
to Doxorubicin and Docetaxel treatment. The cells were plated on 96 wells and infected with lentivirus encoding Pim-1 siRNA or vector control
siRNA. At postinfection for 48 h, cells were treated with DOX (T24, 2.5 and 5μg/ml; UM-UC-3, 1.25 and 2.5 μg/ml) and DTX (T24, 25 and 50 nm;
UM-UC-3, 2.5 and 5 nm) for another 48 h. The cell viability was assessed by WST-1 assay.*, p < 0.05 compared with the control; **, p < 0.01
compared with control.
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reported in hematolymphoid malignancies and solid
cancers [4,5]. Pim-1 has been asserted to promote
tumorigenesis through multiple mechanisms, including
its interaction with other proteins such as c-myc,
p27
KIP1,p 2 1
Cip1/WAF1, Bad, Cdc25A/C dual specificity
phosphates, androgen receptors and its ability to induce
genomic instability [19-22]. The oncogenic effect of
Pim-1 on non-haematopoietic malignancies is currently
under investigation. Ellwood-Yen et al demonstrated
that the overexpression of Pim-1, in cooperation with
increased levels of c-myc, could lead to murine prostatic
intraepithelial neoplasia and invasive adenocarcinoma in
c-myc transgenic mice [23]. Taking into account the
biological role of Pim-1 as an oncoprotein involved in
cell cycle regulation and proliferative processes, our
results suggested possible implication of Pim-1 in the
initiation of bladder carcinogenesis. Moreover, upregula-
tion of Pim-1 in invasive bladder cancer compared with
Non-invasive tumors indicated that Pim-1 also may also
contribute to bladder cancer progression.
Pim-1 has been considered as a survival kinase. Inhibi-
tion of Pim-1 results in a significant growth repression of
prostate cancer cell [24]. Several inhibitors of Pim-1 have
been shown to inhibit the growth of cancer cells, such as
leukemic cells as well as prostate cancer cells. There are
clinical trials to explore the safety of one of the Pim-1
inhibitor, SGI-1776, for the treatment of refractory non-
Hodgkin’s lymphoma and prostate cancer [25,26]. It also
has been demonstrated that Pim-1 monoclonal antibody
(mAb) could induce apoptosis in cancers cells of the
prostate, breast and colon. Furthermore, the inhibition of
Pim-1 function by treatment with Pim-1 siRNA, Pim-1
inhibitors or Pim-1 mAb sensitizes cancer cells to che-
motherapy [15,27-29]. It is noteworthy that Pim-1 inter-
acted and phosphorylated Bad, Etk and BCRP leading to
antagonism of drug-induced apoptosis [14,17,18]. In
bladder cancer, after an initial transurethral resection of
bladder tumor (TURBT), adjuvant intravesical therapy is
another treatment strategy used to reduce the risk of
recurrence. However, the cancer recurrence rate is still
high and the recurring cancer cells can become more
resistant to further intravesical chemotherapy. It is neces-
sary to identify an effective strategy to counter act chal-
lenges associated with clinical management of bladder
cancer patients. In this regard, Pim-1 might be one of the
potential therapeutic targets for the treatment of bladder
cancer and further studies examining Pim-1 as a target of
therapeutics are worthy of investigation.
Conclusions
To the best of our knowledge, this is the first report
showing overexpression of Pim-1 in bladder cancer and
its association with bladderc a n c e rc e l ls u r v i v a l ,d r u g
resistance and tumor progression. The current study
offers significant information on the role and functions
of Pim-1 in bladder cancer, and may aid in the develop-
ment of novel therapy.
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